2019 |
03/07 | 971 | 976 | 950 | 954 | -1.24% | 109,500 | 402億3190万 | +0.42% |
03/06 | 975 | 975 | 955 | 966 | +1.15% | 86,000 | 407億3796万 | +1.79% |
03/06 | 8:00 東京慈恵会医科大学との共同研究開始のお知らせ |
03/05 | 960 | 975 | 950 | 955 | -4.4% | 226,000 | 402億7407万 | +0.53% |
03/05 | 8:00 欧州(ドイツ)子会社の設立のお知らせ |
03/04 | 1,012 | 1,027 | 988 | 999 | -1.77% | 113,100 | 421億2963万 | +4.94% |
03/01 | 1,030 | 1,045 | 1,013 | 1,017 | -1.83% | 135,700 | 428億8873万 | +6.83% |
03/01 | 8:00 MN-166を用いたグリオブラストーマ(神経膠芽腫)のin vitroおよび動物モデルスタディに関する論文掲載のお知らせ |
02/28 | 1,090 | 1,097 | 1,033 | 1,036 | -3.54% | 266,500 | 436億8999万 | +8.82% |
02/27 | 993 | 1,079 | 990 | 1,074 | +9.37% | 467,000 | 452億9252万 | +13.05% |
02/26 | 952 | 998 | 943 | 982 | +2.83% | 246,100 | 414億1271万 | +3.59% |
02/25 | 970 | 970 | 946 | 955 | +0.42% | 121,100 | 402億7407万 | +0.53% |
02/22 | 939 | 961 | 930 | 951 | -0.73% | 122,400 | 401億539万 | -0.42% |
02/21 | 933 | 969 | 921 | 958 | +1.16% | 116,800 | 404億59万 | -0.31% |
02/20 | 994 | 995 | 945 | 947 | -4.63% | 178,400 | 398億5099万 | -1.97% |
02/19 | 960 | 1,000 | 923 | 993 | +4.53% | 303,000 | 417億8673万 | +2.48% |
02/18 | 935 | 950 | 903 | 950 | +18.75% | 560,600 | 399億7724万 | -2.16% |
02/15 | 13:30 2018年12月期決算説明会資料 |
02/15 | 771 | 864 | 758 | 800 | +5.82% | 1,084,400 | 336億6504万 | -17.78% |
02/14 | 910 | 918 | 756 | 756 | -16.56% | 790,100 | 318億1346万 | -22.94% |
02/14 | 8:30 2018年12月期決算短信〔米国基準〕(連結) |
02/13 | 926 | 930 | 902 | 906 | -0.66% | 118,100 | 381億2566万 | -8.67% |
02/12 | 907 | 924 | 900 | 912 | +0.55% | 105,400 | 383億7815万 | -8.25% |
02/08 | 900 | 913 | 898 | 907 | -1.52% | 79,200 | 381億6774万 | -8.84% |
02/07 | 938 | 947 | 917 | 921 | -2.95% | 129,800 | 387億5688万 | -7.34% |
02/06 | 952 | 972 | 940 | 949 | +0.85% | 70,800 | 399億3515万 | -4.33% |
02/05 | 970 | 974 | 936 | 941 | -3.19% | 130,000 | 395億9850万 | -4.66% |
02/04 | 979 | 990 | 968 | 972 | 0% | 49,300 | 409億302万 | -1.02% |
02/01 | 978 | 999 | 951 | 972 | -0.51% | 57,400 | 409億302万 | -0.61% |
01/31 | 955 | 995 | 950 | 977 | +5.51% | 108,600 | 411億1343万 | +0.31% |
01/30 | 955 | 965 | 912 | 926 | -6.28% | 250,900 | 389億6728万 | -5.03% |
01/29 | 983 | 1,010 | 980 | 988 | -1.1% | 81,000 | 415億7633万 | +0.92% |
01/28 | 1,020 | 1,022 | 993 | 999 | -2.06% | 53,500 | 420億3922万 | +1.94% |
01/25 | 1,002 | 1,031 | 1,002 | 1,020 | +2% | 68,900 | 429億2293万 | +3.98% |
01/24 | 983 | 1,015 | 974 | 1,000 | +0.2% | 79,600 | 420億8130万 | +1.73% |
01/23 | 1,000 | 1,015 | 982 | 998 | -2.92% | 127,800 | 419億9714万 | +1.42% |
01/23 | 8:00 定時株主総会にかかる基準日のお知らせ |
01/22 | 1,080 | 1,109 | 1,020 | 1,028 | +0.88% | 269,200 | 432億5958万 | +4.47% |
01/22 | 8:00 MN-166とリルゾール併用療法でのALS(筋萎縮性側索硬化症)およびその他の神経変性疾患を適応とする特許承認のお知らせ |
01/21 | 1,074 | 1,088 | 1,010 | 1,019 | -6.43% | 166,500 | 428億8085万 | +3.77% |
01/18 | 1,101 | 1,110 | 1,081 | 1,089 | -1% | 141,600 | 456億874万 | +10.9% |
01/17 | 1,088 | 1,110 | 1,073 | 1,100 | +3% | 281,700 | 460億6943万 | +12.13% |
01/16 | 15:30 平成30年12月期決算説明会の開始時間変更に関するお知らせ |
01/16 | 15:30 ストックオプション(新株予約権)の発行に関するお知らせ |
01/16 | 1,050 | 1,088 | 1,042 | 1,068 | +2.3% | 171,000 | 447億2923万 | +8.87% |
01/15 | 1,028 | 1,053 | 1,000 | 1,044 | +0.19% | 131,500 | 437億2408万 | +6.31% |
01/11 | 1,002 | 1,045 | 992 | 1,042 | +4.72% | 181,000 | 436億4032万 | +5.89% |
01/10 | 1,021 | 1,022 | 989 | 995 | -0.6% | 128,200 | 416億7189万 | +0.81% |
01/09 | 15:30 平成30年12月期決算発表および決算説明会のお知らせ |
01/09 | 1,053 | 1,053 | 990 | 1,001 | -2.34% | 261,000 | 419億2318万 | +0.81% |
01/09 | 8:00 再発性グリオブラストーマ(神経膠芽腫(GBM))を適応とするMN-166(イブジラスト)とTMZ(テモゾロミド)の併用療法の患者登録開始のおしらせ |
01/08 | 987 | 1,037 | 961 | 1,025 | +8.35% | 281,200 | 429億2833万 | +2.71% |
01/08 | 8:00 MN-001及びMN-002の“線維症・線維化疾患”を適応とする日本における特許承認のお知らせ |
01/07 | 970 | 980 | 939 | 946 | +0.85% | 127,200 | 396億1971万 | -5.68% |
01/04 | 860 | 969 | 843 | 938 | +4.57% | 164,000 | 392億8466万 | -7.13% |
2018 |
12/28 | 865 | 897 | 850 | 897 | +2.75% | 162,900 | 375億6753万 | -11.63% |
12/27 | 863 | 884 | 841 | 873 | +6.59% | 221,000 | 365億6238万 | -14.58% |
12/26 | 840 | 849 | 795 | 819 | +0.86% | 225,000 | 343億78万 | -20.49% |
12/25 | 850 | 858 | 794 | 812 | -7.52% | 576,600 | 340億762万 | -22.07% |
12/21 | 839 | 948 | 791 | 878 | +0.34% | 396,500 | 367億7178万 | -16.7% |
12/20 | 975 | 975 | 849 | 875 | -12.41% | 664,500 | 366億4614万 | -17.84% |
12/19 | 1,019 | 1,019 | 990 | 999 | -1.28% | 90,200 | 418億3942万 | -7.07% |
12/18 | 1,034 | 1,041 | 999 | 1,012 | -1.08% | 127,100 | 423億8388万 | -6.3% |
12/17 | 999 | 1,033 | 997 | 1,023 | -0.2% | 73,700 | 428億4457万 | -5.63% |
12/14 | 1,045 | 1,055 | 1,005 | 1,025 | -3.39% | 94,900 | 429億2833万 | -6.05% |
12/13 | 1,060 | 1,070 | 1,028 | 1,061 | +2.22% | 170,400 | 444億3606万 | -3.55% |
12/12 | 20:00 J.P.モルガン・ヘルスケア・カンファレンス2019への参加のお知らせ |
12/12 | 1,010 | 1,044 | 1,007 | 1,038 | +5.49% | 91,600 | 434億7279万 | -6.57% |
12/11 | 988 | 1,007 | 974 | 984 | +0.41% | 147,700 | 412億1120万 | -12.22% |
12/10 | 1,020 | 1,034 | 963 | 980 | -4.95% | 236,400 | 410億4367万 | -13.27% |
12/07 | 1,078 | 1,078 | 1,024 | 1,031 | -2.27% | 104,400 | 431億7962万 | -9.48% |
12/06 | 1,088 | 1,100 | 1,033 | 1,055 | -4% | 166,700 | 441億8477万 | -7.86% |
12/05 | 1,092 | 1,117 | 1,080 | 1,099 | +0.73% | 120,200 | 460億2755万 | -4.18% |
12/04 | 1,103 | 1,124 | 1,088 | 1,091 | -1.18% | 154,200 | 456億9250万 | -4.63% |
12/03 | 1,120 | 1,125 | 1,091 | 1,104 | -1.43% | 150,600 | 462億3696万 | -3.33% |
11/30 | 1,133 | 1,150 | 1,100 | 1,120 | -2.18% | 117,500 | 469億706万 | -1.67% |
11/29 | 1,149 | 1,156 | 1,132 | 1,145 | +1.42% | 115,600 | 479億5409万 | +0.88% |
11/28 | 1,140 | 1,147 | 1,123 | 1,129 | -1.74% | 92,300 | 472億8399万 | -0.62% |
11/27 | 1,133 | 1,157 | 1,119 | 1,149 | +4.08% | 149,600 | 481億2162万 | +1.14% |
11/26 | 1,098 | 1,109 | 1,077 | 1,104 | +2.32% | 83,200 | 462億3696万 | -2.99% |
11/22 | 1,064 | 1,095 | 1,046 | 1,079 | +2.08% | 114,300 | 451億8992万 | -5.52% |
11/21 | 15:30 TOKYO MX(東京メトロポリタンテレビジョン)「ザ・ビジョナリー~異才の花押~」当社社長兼CEO岩城裕一の出演のお知らせ |
11/21 | 1,055 | 1,079 | 1,046 | 1,057 | -3.12% | 162,100 | 442億6854万 | -8.01% |
11/20 | 1,100 | 1,110 | 1,089 | 1,091 | -2.33% | 90,400 | 456億9006万 | -5.79% |
11/19 | 1,075 | 1,137 | 1,072 | 1,117 | +0.27% | 167,000 | 467億7892万 | -4.2% |
11/16 | 1,136 | 1,149 | 1,100 | 1,114 | -2.02% | 87,900 | 466億5328万 | -4.95% |
11/15 | 1,085 | 1,145 | 1,082 | 1,137 | 0% | 139,900 | 476億1650万 | -3.48% |
11/14 | 1,158 | 1,180 | 1,131 | 1,137 | +0.71% | 156,400 | 476億1650万 | -3.73% |
11/13 | 1,051 | 1,175 | 1,051 | 1,129 | +2.54% | 274,500 | 472億8147万 | -4.97% |
11/12 | 1,153 | 1,169 | 1,097 | 1,101 | -8.02% | 344,100 | 461億885万 | -8.1% |
11/09 | 1,210 | 1,233 | 1,180 | 1,197 | -4.01% | 359,500 | 501億2925万 | -1.16% |
11/08 | 1,350 | 1,355 | 1,235 | 1,247 | -6.45% | 601,700 | 522億2320万 | +2.3% |
11/07 | 1,315 | 1,377 | 1,309 | 1,333 | +2.62% | 371,500 | 558億2480万 | +8.82% |
11/06 | 1,210 | 1,300 | 1,210 | 1,299 | +7.71% | 247,600 | 544億91万 | +5.61% |
11/05 | 1,198 | 1,235 | 1,196 | 1,206 | +0.75% | 115,100 | 505億616万 | -2.51% |
11/02 | 1,205 | 1,221 | 1,180 | 1,197 | +1.01% | 188,400 | 501億2925万 | -3.86% |
11/01 | 1,100 | 1,224 | 1,073 | 1,185 | +7.73% | 167,500 | 496億2670万 | -5.28% |
10/31 | 1,079 | 1,115 | 1,061 | 1,100 | +6.18% | 200,600 | 460億6698万 | -12.7% |
10/30 | 990 | 1,068 | 983 | 1,036 | +1.07% | 230,400 | 433億8671万 | -18.3% |
10/29 | 1,050 | 1,070 | 1,005 | 1,025 | -1.54% | 142,600 | 429億2604万 | -19.92% |
10/26 | 1,050 | 1,068 | 991 | 1,041 | +2.26% | 249,500 | 435億9611万 | -19.36% |
10/26 | 8:30 2018年12月期第3四半期決算短信〔米国基準〕(連結) |
10/25 | 1,049 | 1,085 | 1,009 | 1,018 | -12.92% | 504,600 | 426億3289万 | -21.63% |
10/24 | 1,145 | 1,173 | 1,102 | 1,169 | +2.54% | 225,900 | 489億5663万 | -10.7% |
10/23 | 1,185 | 1,205 | 1,139 | 1,140 | -4.52% | 205,800 | 477億4214万 | -13.18% |
10/22 | 1,181 | 1,206 | 1,155 | 1,194 | -1.49% | 238,500 | 500億361万 | -9.48% |
10/19 | 15:30 四半期報告書の提出期限延長に関する書面の提出のお知らせ |
10/19 | 1,218 | 1,223 | 1,182 | 1,212 | -3.04% | 253,300 | 507億5743万 | -8.25% |
10/18 | 1,284 | 1,284 | 1,248 | 1,250 | -2.19% | 106,300 | 523億4884万 | -5.59% |
10/17 | 1,309 | 1,309 | 1,278 | 1,278 | -0.08% | 114,900 | 535億2145万 | -3.62% |
10/16 | 1,290 | 1,295 | 1,265 | 1,279 | -0.23% | 78,200 | 535億6333万 | -3.54% |
10/15 | 1,273 | 1,300 | 1,240 | 1,282 | +0.94% | 153,100 | 536億8897万 | -3.32% |
10/12 | 1,184 | 1,286 | 1,183 | 1,270 | +4.79% | 192,900 | 531億8642万 | -4.3% |
10/11 | 1,196 | 1,245 | 1,150 | 1,212 | -7.27% | 517,200 | 507億5743万 | -9.01% |
10/10 | 1,355 | 1,392 | 1,296 | 1,307 | -5.08% | 338,100 | 547億3594万 | -2.46% |
10/09 | 1,373 | 1,404 | 1,354 | 1,377 | -3.57% | 239,300 | 576億6748万 | +2.76% |
10/05 | 8:00 MN-166のグリオブラストーマ(神経膠芽腫)治療適応に対するFDAのオーファンドラッグ指定のお知らせ |
10/04 | 8:00 BioJapan 2018にて登壇のお知らせ |